Business Wire

CA-XPRIZE

Share
XPRIZE Responds to COVID-19 by Uniting a Global Alliance of Innovators to Find Unconventional Solutions to Pandemic Threats

XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, reveals the XPRIZE Pandemic Alliance, a global coalition that combines the power of collaboration, competition, shared innovation and radical thinking to accelerate solutions that can be applied to COVID-19 and future pandemics.

The XPRIZE Pandemic Alliance launched to address the immediate needs of the COVID-19 crisis by expanding visibility into solutions underway. This launch comes with an open call to arms to the world’s innovators, clinicians, researchers, data scientists, institutions, and experts to join the Alliance and share existing work and resources using covid19.xprize.org . This website will allow the global community to:

  • Participate in the latest breakthroughs, research and solutions in development;
  • Make asks of what they need and allow XPRIZE, the Alliance members and their vast network of supporters and partners to offer their resources to help enable and accelerate innovators to reach their goals faster.

In the immediate term, the Alliance will focus on areas such as accelerating solutions for remote care, provisioning personal protective equipment to the front lines, increasing access to testing, and improving food and medicine security for vulnerable populations, among others.

As part of this Alliance, researchers and scientists are invited to share and access data through the XPRIZE Data Collaborative, a unique platform for researchers and innovators to collaborate, share and learn from data in a broad spectrum of fields in their search for solutions. This trove of data aims to unlock new approaches to fighting pandemics and will serve as the backbone to the collective effort that will prepare us for additional pandemic spikes like COVID-19, or other viral threats.

As part of the XPRIZE Data Collaborative, our launch partner, Anthem, is taking the lead by providing vetted partners with access to one of the largest certified deidentified data set including years of longitudinal data for prior viral outbreaks (e.g., swine flu, avian flu, influenza).

XPRIZE will also host and launch a series of rapid data challenges in support of the Alliance’s initiatives, which may include developing an early warning system for future pandemics, predictive models for public health resource allocation, more efficient and affordable diagnostics, treatments and cures that can be rapidly reproduced, or others based on insights drawn from the collaborators.

Other notable global partners that have already agreed to join the Alliance include United States Department of Veterans Affairs, Ending Pandemics, Intel, Illumina, IEEE Standards Association, MIT Solve, C2 International, Cloudbreak Health, the Foundation Botnar, McGill University, Nvidia, the Patrick J. McGovern Foundation, PPE Coalition, and UCSD. XPRIZE is actively calling for more partners and members to join the Alliance.

“There are few times in recent history when one pandemic has affected so many people, but with all of us focused on one problem, it means impact and solutions will only be accelerated, and we’re excited to work with Anthem to amplify the potential of this platform in quickly enabling global talent to join the fight,” said XPRIZE CEO Anousheh Ansari . “At XPRIZE, we believe radical breakthroughs can come from anyone, anywhere, and our response to COVID-19 will help provide solutions when humanity’s most vulnerable need it most.”

“In this time of crisis, we see an opportunity to come together as a community via the powerful XPRIZE platform to address the most acute needs in the system today and to accelerate new solutions: from protecting our healthcare workers at the front lines and proactively taking care of the high risk populations to developing new approaches to diagnostics, therapy and vaccines,” said Rajeev Ronanki, Chief Digital Officer at Anthem.

“COVID-19 is not the first, nor the last pandemic humanity will face, and future pandemics could be far worse,” said XPRIZE Founder and Executive Chairman Peter H. Diamandis , MD. “For 25 years, XPRIZE has focused on solving global grand challenges, crowdsourcing solutions. The XPRIZE does this by inspiring innovators around the world to use exponential technologies to address problems in unbelievably short timeframes. The XPRIZE Pandemic Alliance will leverage data and human collaboration like never before to facilitate technological breakthroughs for the benefit of humankind.”

For more information, visit covid19.xprize.org .

Additional Quotes from XPRIZE Pandemic Alliance Partners:

“Technology can play a role in helping us to address the world’s largest challenges,” said Stacey Shulman, Chief Innovation Officer and VP, IOT Group, Intel. “Intel is partnering with XPRIZE to enable the larger community to find creative and impactful solutions for this global pandemic.”

“Never before have we had both the technology and collective will to develop a proactive global network for real time assessment and monitoring of infectious epidemics,” said Dr. Phil Febbo, Senior Vice President and Chief Medical Officer, Illumina. “We are pleased to be participating and helping to ensure that laboratories using our sequencers worldwide can integrate into a global community committed to preventing pandemics.”

“In response to the ongoing threat of COVID-19, Solve is focused on finding and supporting innovative solutions that address global health preparedness, early detection, and rapid response,” said Alex Amouyel, Executive Director at MIT Solve. “Better data sharing and analysis is one area that is critical in the effort to slow and track the spread of COVID-19 and future disease outbreaks—and Solve is pleased to join the XPRIZE Global Pandemic Data Alliance in that endeavor.”

"We are finding solutions and new innovations guided by lived experience, empathy, and a love of humanity and coming from unexpected and underexplored sources—makers/tinkerers who are also frontline health workers, student inventors, data scientists driven by social purpose," said Vilas Dhar, Trustee of the Patrick J. McGovern Foundation. "This Alliance creates a platform to engage those actors and many more in a shared quest to alleviate suffering and create a new paradigm for pandemic response."

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to accelerate the development of technological breakthroughs that benefit humanity. Active competitions include the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE, the $20 Million NRG COSIA Carbon XPRIZE, and the $10 Million Rainforest XPRIZE. For more information, visit xprize.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press release

Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye